Scores of attempts have been made to deliver biologics orally, and most have failed. We believe Rani’s approach will transform the market, and we are on the way to proving that it is nothing short of a breakthrough. We have tested multiple molecules on our platform, including internal programs and partner molecules. These preclinical tests have consistently demonstrated that the RaniPill™ capsule delivery is equivalent to a subcutaneous injection. We have also completed a successful Phase I study with Octreotide.
“Millions must take injections to slow the progression of their condition. With pills, compliance is much higher than with injections which helps slow down chronic diseases.”
“I am passionate about changing healthcare and coming up with new solutions that will impact the lives of millions of patients.”
“Given the market demand and potential, it’s no wonder that there have been more than a hundred attempts and billions of dollars spent by companies to try to convert painful injections into painless pills.”